|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The following scientific staff and reviewers for Research To Practice reported real or apparent conflicts of interest for themselves (or their spouses/partners), which have been resolved through a conflict of interest resolution process: Aviva Asnis-Alibozek, PA-C, MPAS — Salary: AstraZeneca Pharmaceuticals LP; Shareholder of: AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — Shareholder of: Amgen Inc and Genentech BioOncology. All other Research To Practice staff and external reviewers: No real or apparent conflicts of interest to report.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of
interest, which have been resolved through a conflict of interest resolution process:
Dr Chlebowski —
Professor of Medicine, David Geffen School of Medicine at UCLA; Chief, Division of Medical Oncology
and Hematology, Harbor-UCLA Medical Center, Torrance, California. Consulting Fees: AstraZeneca
Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Fees for Non-CME Services
Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP,
Novartis Pharmaceuticals Corporation. Dr O’Shaughnessy — Co-Director, Breast Cancer Research
Program, Baylor-Charles A Sammons Cancer Center, Texas Oncology, PA, US Oncology, Dallas,
Texas. Consulting Fees: Biogen Idec, Bristol-Myers Squibb Company, Eisai Inc, Eli Lilly and Company,
Genentech BioOncology, Genzyme Corporation, Novartis Pharmaceuticals Corporation, Ortho Biotech
Products LP, Pfizer Inc; Fees for Non-CME Services Received Directly from Commercial Interest or
Their Agents: Abraxis BioScience, Eli Lilly and Company, Sanofi-Aventis. Dr Pegram — Professor of
Medicine, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center,
Miami, Florida. Consulting Fees: Genentech BioOncology, GlaxoSmithKline, Pfizer Inc. Dr Slamon — Professor of Medicine; Chief, Division of Hematology/Oncology; Director of Clinical/Translational
Research, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los
Angeles, California. Fees for Non-CME Services Received Directly from Commercial Interest or Their
Agents: Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis; Ownership Interest: Amgen Inc,
Pfizer Inc. Dr Sledge — Ballve-Lantero Professor of Oncology; Professor of Medicine and Pathology,
Melvin and Bren Simon Indiana University Cancer Center, Indianapolis, Indiana. Consulting Fees:
Genentech BioOncology; Contracted Research: Sanofi-Aventis. Dr Swain — Professor of Medicine,
Georgetown University; Medical Director, Washington Cancer Institute, Washington Hospital Center,
Washington, DC. Consulting Fees: Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc;
Travel for Clinical Investigator Meeting: Genentech BioOncology, Sanofi-Aventis. Dr Winer — Director,
Breast Oncology Center, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard
Medical School, Boston, Massachusetts. No financial interests or affiliations to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
TOPICS
Adjuvant Chemotherapy for Patients with HER2-Negative Disease
Adjuvant Systemic Therapy for Patients with HER2-Positive Disease
Adjuvant Therapy for Elderly Patients with HER2-Positive Disease
Adjuvant Trial Evaluating Trastuzumab and/or Lapatinib in HER2-Positive Disease
- Select publications
Role of Bevacizumab for Patients with HER2-Negative Metastatic Disease
Adjuvant Trial Combining Bevacizumab with Trastuzumab
Optimizing First-Line Systemic Therapy for Patients with ER-Positive, HER2-Positive Metastatic Disease
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
